Linda.Bunschoten

About Linda Bunschoten - Chief Marketing Officer

Linda has 25+ years of experience uncovering pain points and strategizing with companies in the healthcare industry in order to secure and retain more clients. Her chief thinking responsibilities include translating insight into strategy and ensure that all MarCom and Product Management activities contribute to our overall customer experience and meet our industry’s quality expectations.
Aug 2019

Pharma Supply Chain Consortium Selects Cyntegrity for the Innovative MYTIGATE Initiative

By |2019-08-29T09:19:44+00:00August 28, 2019|News|0 Comments

A German pharma supply chain consortium formed by esteemed industry leaders Bayer, Boehringer Ingelheim, Frankfurt University of Applied Sciences, GEFCO, and others, announces its partnership with risk-based quality management pioneer Cyntegrity Germany GmbH.

Jul 2019

Practice-Oriented Research Project “Pharma Supply Chain Risk Management in Air Freight” Started

By |2019-07-10T11:21:08+00:00July 10, 2019|News|0 Comments

Cyntegrity project partner in digitization of pharmaceutical logistics: Frankfurt UAS' research project ensures greater transparency and security in the pharmaceutical supply chain.

Apr 2019

FDA Q&A Draft Guidance Document: The RBM Process-Technology Fit

By |2019-05-27T15:16:11+00:00April 15, 2019|Blog|0 Comments

Our expert team reviewed the March 2019 RBM Q&A draft guidance document and extended the FDA guidance with RBM solution specific insights and a MindMap to help you even further.

Mar 2019

Your Practical Guide to Understanding Clinical KRIs

By |2019-03-20T10:55:19+00:00March 12, 2019|Infographic, News|0 Comments

Our key risk indicator infographic will give you a foundational understanding of KRIs, provide valuable examples of KRIs, and guide you towards getting started with your risk-based monitoring (RBM) program.

Feb 2019

3 Critical Aspects of Clinical Trial Conduct that Affect the Totality of Evidence

By |2019-02-27T20:13:40+00:00February 27, 2019|Blog|0 Comments

Even without it being mandated, health authorities typically expect pharma and biotech companies to conduct two well-controlled Phase 3 trials demonstrating efficacy and safety. Still today this principle ensues discussions regarding the quantity and quality of the evidence needed to establish effectiveness.

Upcoming Events

There are no upcoming events at this time.

Register Today!

Get Free Test Access